Company |
Partner |
Amt. |
Details |
Date |
TOTAL: $43.1M (YEAR TO DATE: $43.1M) | ||||
Evotec AG (Hamburg, Germany) |
Janssen Pharmaceuticals Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) |
ND |
For the identification and selection of novel targets from Evotec's TargetAD database and for the transition of targets into the drug discovery process |
1/16/15 |
Incyte Corp. (Wilmington, Del.) |
Novartis AG (Basel, Switzerland) |
$25 |
For the EMA's positive opinion of Jakavi (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea |
1/26/15 |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Biogen Idec Inc. (Cambridge, Mass.) |
$7 |
Related to the advancement of the ongoing open-label extension study of ISIS-SMN in children with spinal muscular atrophy |
1/15/15 |
Oncomed Pharmaceuticals Inc. (Redwood City, Calif.) |
Glaxosmithkline plc (London) |
$5 |
For enrolling the first biomarker-selected patient in its anti-Notch1 antibody phase Ia solid tumor clinical trial |
1/16/15 |
Paratek Pharmaceuticals Inc. (Boston) |
Actavis plc (Dublin) |
$4 |
Under the terms of the companies' collaboration to develop sarecycline (WC3035) in moderate to severe acne, with the commencement of phase III trials |
1/7/15 |
Repligen Corp. (Waltham, Mass.) |
Pfizer Inc. (New York) |
$1 |
Under the terms of the companies' exclusive worldwide agreement to develop compounds to potentially treat spinal muscular atrophy |
1/9/15 |
Txcell SA (Valbonne, France) |
Trizell Holding SA (Lausanne, Switzerland) |
$1.1 |
As part of the Ovasave collaboration option, development and license agreement, triggered by the first patient enrolled in a phase IIb trial of Ovasave, a personalized T-cell immunotherapy, for refractory Crohn's disease |
1/30/15 |
|
Notes Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. This chart includes only biotech companies that develop therapeutics. ND = Not disclosed. | ||||